Vera Therapeutics reports two-year data showing Trutakna stabilizes kidney function in IgA nephropathy, paving way for full FDA approval

Vera Therapeutics announced that its recently approved drug Trutakna has produced encouraging two-year results in patients with IgA nephropathy, a chronic autoimmune kidney disease.

The data indicate that Trutakna helped stabilize kidney function over the study period, supporting its therapeutic benefit and positioning the company for a subsequent full FDA submission.

If the agency grants full approval, Trutakna could become a key treatment option for IgA nephropathy, expanding Vera's portfolio and offering a new avenue for patients with limited options.